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A recombinant capripox virus was constructed containing a cDNA copy of genome segment 7 of bluetongue virus (BTV)
serotype 1 from South Africa (BTV 1SA), which expressed high levels of the major BTV core protein VP7 in infected lamb
testis (LT) cells. Sheep vaccinated with this recombinant virus developed antibodies to VP7 (detected by ELISA) but no
neutralizing antibodies to either the homologous or heterologous BTV serotype, prior to challenge (BTV 1 or BTV 3, respec-
tively). Following challenge with a virulent heterotypic strain of BTV (BTV3 SA), all of the animals developed clinical signs
of disease, indicating that they were infected and that the challenge virus did replicate. While all of the control animals
died, six of the eight animals that were vaccinated with the recombinant capripox virus expressing VP7 recovered fully.
This is the first report of a significant level of cross serotype protection against the lethal effects of a challenge with virulent
BTV, produced by vaccination with a single BTV core protein, which did not generate a neutralizing antibody response.
q 1996 Academic Press, Inc.
Bluetongue is an economically important nonconta- live viruses for vaccination is likely to increase the
gious disease of sheep and cattle. The causative agent chances of reassortment between vaccine strains or be-
bluetongue virus (BTV), transmitted by Culicoides spe- tween vaccine and wild-type viruses and could therefore
cies (1), is the prototype member of the orbivirus ge- generate novel progeny strains, which pose a greater
nus, within the family Reoviridae. There are 24 known disease threat or are less easy to control with the avail-
serotypes of BTV, identified by serum neutralization able vaccines. Attenuated strains of BTV used as vac-
tests (2), which after a single vaccination do not exhibit cines can also have teratogenic effects in sheep and
long-term cross-protection and only generate neu- cows (10, 11). These observations provide impetus for
tralizing antibodies to the homologous serotype (3, 4). the development of alternative, noninfectious and/or sub-
However, serial vaccinations with live attenuated BTV unit BTV vaccines (12).
of different serotypes can generate a broad neutraliz- The BTV core contains two major structural proteins
ing antibody response to additional virus serotypes not (VP3 and VP7) and three distinct minor proteins (VP1,
previously encountered (4, 5). In South Africa, three VP4, and VP6/VP6a), which surround the 10 dsRNA ge-
pentavalent vaccines are currently used at 3-week in- nome segments (13–15). The outer capsid layer is com-
tervals (containing a total of 15 attenuated live viruses, posed of two additional major structural proteins (VP2
of different serotypes). and VP5) and may be associated with small amounts of
Genome segment reassortment can occur between one of the nonstructural proteins (NS2). These outer coat
different BTV strains in cell cultures, mammalian hosts, proteins are involved in cell attachment and penetration,
or insect vectors (6). Reassortant strains of BTV, African demonstrated by the large relative reduction in the infec-
Horsesickness virus (AHSV), or Kemerovo serogroup or- tivity of core particles for mammalian cells (15). VP2 and
biviruses have been characterized which have novel anti- VP5 are the most variable of the BTV proteins and VP2
genic or virulence phenotypes (7–9). The use of multiple in particular varies in a serotype-specific manner (16,
17). VP2 and to a lesser extent VP5 have also been shown
to be involved in the generation as well as the specificity
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227
0042-6822/96 $18.00
Copyright q 1996 by Academic Press, Inc.
All rights of reproduction in any form reserved.
AID VY 7941 / 6a17$$$441 05-07-96 01:13:44 vira AP: Virology
228 SHORT COMMUNICATION
protect sheep against challenge with virulent virus of the
same serotype (18, 23, 24), although the titer of neutraliz-
ing antibodies produced and the level of protection ob-
served were greater if VP2 and VP5 were used together.
Although these data indicate that BTV outer capsid pro-
teins may be useful subunit vaccine components, the
protective immune response was serotype-specific and
appeared to correlate with the levels of neutralizing anti-
bodies. The outer capsid proteins of a single BTV sero-
type are therefore unlikely to generate significant protec-
tion against the other 23 serotypes, limiting their value
for vaccination.
Jeggo et al. (25) showed that there was no correlation
between the degree of protection and the level of neu-
tralizing antibody produced after vaccination with ‘‘live’’
FIG. 1. Immunoprecipitation of BTV proteins synthesized in LT cells.BTV, even if the vaccine and challenge viruses are of the
Lysates of cells which were uninfected (lanes 6 and 9), or infected with
same serotype. This implies that although neutralizing the parental KS-1 CPV (lanes 5 and 8), rCPV.BTV1.VP7 (lanes 1, 2, 3,
antibodies may play a role in protection, other factors or and 7), or BTV1SA (lanes 4 and 10), were labeled with [35S]methionine.
The BTV proteins were immunoprecipitated with guinea pig polyclonalmechanisms are also involved. This has been confirmed
antiserum raised against either BTV1SA (lanes 1, 4, 5, and 6), BTV3by Stott et al. (26) who reported the protection of animals
(lane 2), or BTV10 (lane 3) or with the A3 monoclonal antibody (specificby cell-mediated immunity. Adoptive cell transfer studies
for VP7 (36)) (lanes 7, 8, 9, and 10). The precipitated proteins were
in monozygotic sheep demonstrated serotype cross-re- analyzed by SDS–PAGE (35). The migration positions of the major BTV
active cell-mediated immunity, in the absence of neu- structural and nonstructural proteins are indicated.
tralizing antibodies, although this protection is normally
short-lived (2 weeks) (3, 27). Immunodominant serotype
cross-reactive T-cell determinants have been located the 2.5-kb HindIII S fragment of the KS-1-attenuated strain
of CPV (33). A recombinant CPV (rCPV.BTV1.VP7) waswithin the structural proteins of BTV cores (28) and sero-
type cross-reactive T-cell epitopes have been identified generated by homologous recombination in primary lamb
testis (LT) cell cultures infected with the KS-1 Pirbrightwithin VP7 (29). VP7 is a major BTV group reactive anti-
gen (30) and was immunodominant during monoclonal vaccine strain of CPV and cotransfected with the plasmid
vector pCR-3, as previously described (34). LT cells in-antibody production using in vitro priming techniques
(31). These data led us to consider VP7 as a possible fected with this recombinant virus, synthesized a protein
that coelectrophoresed with authentic BTV 1SA VP7 dur-candidate for use in recombinant subunit vaccines,
which might induce a protective and serotype cross reac- ing SDS–PAGE (35) (Fig. 1), which was not made in cells
infected with the CPV vaccine isolate (KS-1). This proteintive immune response to BTV (possibly via a cell medi-
ated mechanism). was immunoprecipitated by polyclonal antiserum to BTV
1SA, BTV 3, or BTV 10 and by the VP7-specific mABVaccinia virus is one of the most commonly used virus
vectors for the generation of recombinant vaccines. How- A3 (36), identifying it as the BTV serotype cross-reactive
antigen and major core protein, VP7 (Fig. 1). LT cellsever, it is capable of infecting many different species in
addition to those hosts (cattle and sheep) which are tar- infected with rCPV.BTV1.VP7 and examined by indirect
immuno-fluorescence using mAB A3 showed a high levelgets for vaccination against BTV. In contrast capripox-
virus (CPV) has a restricted host range (cattle, sheep, and of generalized diffuse staining as well as intensely
stained cytoplasmic aggregates of VP7, which were notgoats) and therefore its use as the basis of a recombinant
vaccine for BTV would represent a more limited replica- present in cells infected with KS-1 (Fig. 2).
Eight cross-bred Dorset horn sheep, 1–2 years old,tion hazard in the field.
A plasmid transfer vector (pCR-3) was constructed housed in insect-proof loose boxes in the high security
isolation units at the Institute for Animal Health, Pirbright,containing the full-length cDNA clone of genome seg-
ment 7 (encoding VP7) of BTV serotype 1 from South were vaccinated by two subcutaneous injections in the
neck region of 1.5 1 107 plaque forming units (PFU) ofAfrica (BTV1 SA) (32), under the control of the vaccinia
virus (VV) major late promoter p11. This plasmid also rCPV.BTV1.VP7, given 21 days apart. Four control ani-
mals of similar age received 2 1 107 PFU of the parentalcontains, in the opposite orientation, the Escherichia coli
dominant selectable marker gene, xanthine-guanine CPV strain (KS-1). Two further control animals were not
vaccinated. Two weeks after the second vaccination allphosphoribosyltransferase (Eco gpt) under the control of
the VV major early/late promoter, p7.5. These two genes 14 sheep received a normally lethal challenge by subcu-
taneous inoculation of 5.2 log10 50% egg lethal doseand their respective promoters were flanked by the entire
capripox virus (CPV) thymidine kinase (TK) gene within (ELD50) of a virulent strain of BTV3 SA (isolate SA535,
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FIG. 2. Immunofluorescence in LT cells infected with either rCPV.BTV1.VP7 (A) or with the parental CPV KS-1 strain (B). Subconfluent cultures
of LT cells, in Lab-Tek chamber slides, were infected with rCPV.BTV1.VP7 or KS-1 at  104 plaque forming units (PFU) per well. On observation
of cytopathic effect (CPE) the monolayers were rinsed in PBS, fixed for 2 min in acetone/methanol (1:1; v/v), and then incubated for 1 hr at 377
with an anti-VP7 monoclonal antibody, A3 (36). The cell monolayers were rinsed thoroughly with PBS / 1% Triton X-100 and then reacted for 1
hr at 377 with a 1:20 dilution of FITC-labeled rabbit anti-mouse IgG. All antibodies were diluted in PBS / 3% BSA. The slides were rinsed three
times as before, mounted in glycerol/PBS (1:1; v/v), viewed using a Leitz fluorescent microscope, and photographed using identical exposure
conditions.
from Dr. B. Erasmus, Onderstepoort). Rectal tempera-
tures were measured daily and the animals monitored
for clinical signs of disease. Blood samples were taken
for serology at weekly intervals. Sheep inoculated with
the rCPV.BTV1.VP7 produced high levels of anti-BTV VP7
antibodies, measured by competitive ELISA, reaching
successive maxima 2 weeks after the first immunization
and 1 week after the second (Fig. 3). After challenge, the
antibody levels against VP7 increased further reaching
a new maximum (Fig. 3) and remained high for the re-
mainder of the experiment (until death or up to 4 weeks
postchallenge). Although, the control sheep, both unvac-
cinated and those vaccinated with KS-1, did not show
significant levels of antibodies to VP7 before the chal-
lenge, their VP7 antibody levels rose rapidly following
challenge, prior to death (Fig. 3). After challenge all of the
sheep, including those vaccinated with rCPV.BTV1.VP7,
FIG. 3. A competitive ELISA (36) was used to determine the levelsshowed clinical signs of bluetongue, including fever (up
of anti-BTV VP7 antibodies circulating in the sheep used in the vaccina-to 417), coronitis, conjunctivitis, and oedema of the lips
tion trial. Results from individual sheep sera were averaged for theand muzzle, indicating that in each case they were in-
surviving animals in each group (see Table 1) (vaccinated with
fected and the challenge virus had replicated. However, rCPV.BTV1.VP7 (l), KS-1 (h), or unvaccinated (s)). Sheep were vacci-
six of eight (75%) of the animals vaccinated with the nated twice (V1 and V2), 3 weeks apart and then challenged at 5 weeks
with BTV3 SA.recombinant capripox virus rCPV.BTV1.VP7 recovered
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TABLE 1
Neutralizing Antibody Titers to BTV-3 in Vaccinated and Unvaccinated Sheep
Weeks postvaccination Weeks postchallenge
Sheep
No. Treatment 0V1 1 2 3V2 4 5CH 1 2 3 4
39 rCP.BTV1.VP7 (1.5 1 107 PFU) 10 10 10 10 10 10 10 1280 1280 320
40 rCP.BTV1.VP7 (1.5 1 107 PFU) 10 10 10 10 10 10 10 640 1280 320
41 rCP.BTV1.VP7 (1.5 1 107 PFU) 10 10 10 10 10 10 40 1280 1280 320
42 rCP.BTV1.VP7 (1.5 1 107 PFU) 10 10 10 10 10 10 40 1280 1280 1280
43 rCP.BTV1.VP7 (1.5 1 107 PFU) 10 10 10 10 10 10 20 1280 1280 640
44 rCP.BTV1.VP7 (1.5 1 107 PFU) 10 10 10 10 10 10 40 1280 1280 1280
45 rCP.BTV1.VP7 (1.5 1 107 PFU) 10 10 10 10 10 10 20 1280 1280 Dead
46 rCP.BTV1.VP7 (1.5 1 107 PFU) 10 10 10 10 10 10 80 Dead — —
47 KS-1 (2.0 1 107 PFU) 10 10 10 10 10 10 20 Dead — —
48 KS-1 (2.0 1 107 PFU) 10 10 10 10 10 10 10 Dead — —
49 KS-1 (2.0 1 107 PFU) 10 10 10 10 10 10 80 Dead — —
50 KS-1 (2.0 1 107 PFU) 10 10 10 10 10 10 40 Dead — —
51 Nonvaccinated 10 10 10 10 10 10 40 Dead — —
52 Nonvaccinated 10 10 10 10 10 10 40 1280 1280 Dead
Note. Assays for neutralizing antibodies used methods similar to those described by Parker et al. (41). Serum samples were taken at weekly
intervals from sheep vaccinated with either the recombinant CPV rCPV.BTV1.VP7 (expressing BTV VP7) or the parental KS-1 CPV and from the
unvaccinated control animals. Twofold serial dilutions of serum (50 ml, starting at 1001) were prepared directly in 96-well microtiter tissue culture
plates. An equal volume of medium (50 ml) containing 100 median tissue culture infectious doses (TCID50) of BTV3 SA (or of BTV1 SA, data not
shown) was added and the plates incubated for 1 hr at 377 then overnight at 47. 100 ml of medium containing 2 1 105 BHK21 cells was added to
each well and the plates were incubated at 377. Plates were evaluated daily for CPE, the final reading being taken on Day 5. The neutralizing titer
is defined as the reciprocal of the highest serum dilution that prevented CPE. Sheep were vaccinated twice 3 weeks apart and then challenged at
5 weeks. V1, first vaccination; V2, second vaccination; CH, challenge.
fully and all of the clinical signs had resolved by 4 weeks affected by the prior vaccination and showed no correla-
tion with the protection observed (Table 1). The partialpostchallenge. The surviving animals remained clinically
normal until the end of the experiment (Week 5 postchal- protection of the sheep vaccinated with rCPV-BTV1.7
was not therefore dependent on inactivation of the chal-lenge). Previous experience indicates that the animals
surviving at Week 5 and no longer showing clinical signs lenge virus by preexisting neutralizing antibodies, which
suggests that it may be mediated through a cellularhad fully recovered and were unlikely to succumb as a
result of this BTV challenge at a later date. All of the immune response.
The data presented represent the first demonstrationunvaccinated control animals, as well as those vacci-
nated with wild-type CPV, died within 4 weeks after chal- of a significant protective immune response against the
lethal effects of challenge with a virulent, heterologouslenge (five of six within 14 days). Sheep number 45, vacci-
nated with rCPV.BTV1.VP7 and unvaccinated control serotype of BTV, generated in response to the major
outer core protein and serogroup cross reactive antigensheep number 52, which both died in the fourth week
postchallenge, had inhaled ruminal contents as a result VP7, by itself. This protection was not dependent on virus
neutralization. These results confirm that a viral protein,of smooth muscle lesions in the esophagus and died
of pneumonia. Using Chi square analysis, with Yates’s other than the structural components of the BTV outer
capsid layer, can play an important role in protection,correction for continuity, the response (survival or death)
of the two groups (sheep vaccinated with the recombi- possibly via a cell-mediated mechanism. These observa-
tions are consistent with those of Jeggo et al. (5), whonant capripox virus or the control animals) to subsequent
challenge with virulent BTV3 was found to be significantly were unable to demonstrate any evidence of antibody-
dependent cell-mediated cytotoxicity (ADCC) or comple-different (x2  5.11, df  1, and P  0.025).
None of the sheep used in the trial, including those ment-mediated ADCC in BTV-infected sheep. Stott et al.
(37) showed that an inactivated virus conferred protec-animals vaccinated with the recombinant capripox virus,
developed neutralizing antibodies to BTV1 (results not tion via a cellular immune response, in the absence of
neutralizing antibodies. BTV infection has previouslyshown) and no neutralizing antibodies to BTV3 were
detected prior to the challenge (Table 1). Neutralizing been shown to induce BTV-specific cytotoxic T-cells
(CTLs) in both sheep and mice (38, 39). These BTV-spe-antibody to BTV3 were detected 1 – 3 weeks after chal-
lenge in all of the surviving animals, which is also cific CTLs were serotype cross-reactive (38) and were
able to inhibit BTV replication in vitro (40). Jeggo et al. (39)thought to reflect replication of the challenge virus.
However, the level of neutralization produced was not also used adoptive transfer techniques in monozygotic
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